Agendia Licenses Genetic Profile for Tamoxifen Resistance from Erasmus Medical Center | GenomeWeb
NEW YORK (GenomeWeb News) - Agendia said today that it has signed a license agreement with the Erasmus University Medical Center in Rotterdam, the Netherlands, giving it exclusive rights to a genetic profile that predicts resistance to tamoxifen.
Agendia said it will validate the tamoxifen profile in collaboration with the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.